EUVIMEDEUVIMED entdecken
Crossref

Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn’s Disease—A Risk-Adjusted Propensity Score Matched Analysis

Samuel Raimundo Fernandes iD, Inês Coelho Rodrigues, André Da Silva Neves, Sofia Saraiva, Ana Rita Gonçalves, Paula Moura Santos, Ana Valente, Luís Araújo Correia, Helena Cortez- Pinto, Fernando Magro iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izaf112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Samuel Raimundo Fernandes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Serviço de Gastrenterologia e Hepatologia, Unidade Local de Saúde de Santa Maria, Lisboa, Portugal. Hauptthemen laut MEDLINE: Crohn Disease, Biological Products, Gastrointestinal Agents, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early top-down treatment with biologics has been associated with higher rates of endoscopic remission compared to step-up treatment in Crohn’s disease (CD). The benefits in relation to transmural remission are currently unknown. Better stratification of patients suitable for top-down strategies is needed.

Methods

Retrospective study including CD patients naïve to immunomodulators and biologics and with endoscopic and radiologic evidence of active disease at baseline. Transmural remission rates were compared between patients receiving early top-down treatment (start of biologics within 6 months of immunomodulators) and conventional step-up treatment (start of biologics > 6 months after immunomodulators). The influence of risk factors for disabling disease (age at diagnosis, disease duration, smoking, phenotype, perianal disease, extensive small bowel disease, and elevated C-reactive protein) on transmural remission rates was also assessed and adjusted through propensity score-matched analysis.

Results

In total, 327 patients were included in the main analysis, 47.7% receiving early top-down treatment with biologics. Transmural remission rates decreased from 33.3% to 0% in patients with 0 and 6 risk factors for disabling disease, respectively. Early top-down treatment resulted in higher rates of transmural remission (33.3% vs 18.1%, P = .002) and was an independent predictor for this outcome in the multivariate analysis (odds ratio [OR] 2.187, 95% confidence interval [95% CI], 1.270-3.665, P = .005). Comparable results were found in the propensity score matched analysis (34% vs 17%, P = .002; OR 2.3, 95% CI, 1.268-4.174, P = .006).

Conclusions

Early top-down treatment with biologics improves the rates of transmural remission in CD. Risk factors for disabling disease significantly impact the chances of obtaining transmural remission and may help clinicians identify patients suitable for more aggressive treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseBiological ProductsGastrointestinal AgentsImmunologic FactorsPropensity ScoreRemission InductionRetrospective StudiesPatient SelectionDrug Therapy, CombinationTreatment OutcomeTime FactorsColonoscopyMagnetic Resonance ImagingHumansMaleFemaleYoung AdultAdultMiddle Aged

Stichwörter der Autor:innen

Crohn's diseasedisabling diseasetop-down treatmenttransmural remission

Substanzen

Biological ProductsGastrointestinal AgentsImmunologic Factors

Autor:innen und Institutionen

  • Serviço de Gastrenterologia e Hepatologia, Unidade Local de Saúde de Santa Maria, Lisboa, Portugal.
  • Clínica Universitária de Gastrenterologia. Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal.
  • Grupo de Estudos de Doenças Inflamatórias do Intestino - GEDII, Porto, Portugal.
  • CINTESIS@RISE, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal.

ORCID-Profile: Samuel Raimundo Fernandes, Fernando Magro

Zitieren

APA

Fernandes, S. R., Rodrigues, I. C., Neves, A. D. S., Saraiva, S., Gonçalves, A. R., Santos, P. M., Valente, A., Correia, L. A., Pinto, H. C., & Magro, F. (2025). Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn’s Disease—A Risk-Adjusted Propensity Score Matched Analysis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf112

Vancouver

Fernandes SR, Rodrigues IC, Neves ADS, Saraiva S, Gonçalves AR, Santos PM, et al. Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn’s Disease—A Risk-Adjusted Propensity Score Matched Analysis. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf112

BibTeX
@article{Fernandes2025,
  author = {Fernandes, Samuel Raimundo and Rodrigues, Inês Coelho and Neves, André Da Silva and Saraiva, Sofia and Gonçalves, Ana Rita and Santos, Paula Moura and Valente, Ana and Correia, Luís Araújo and Pinto, Helena Cortez- and Magro, Fernando},
  title = {Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn’s Disease—A Risk-Adjusted Propensity Score Matched Analysis},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izaf112}
}
Kostenlos starten →